Drugs / Anticoagulant Therapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07383155 | Feb 2026 → Dec 2027 expected | acute coronary syndrome, bleeding disorder, vascular-type | Shenyang Northern Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anticoagulant Therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07383155 ↗ |
| Known as | UFH | “bivalirudin vs. unfractionated heparin (UFH) monotherapy” NCT07383155 ↗ |
| Route | Intravenous | “an intravenous UFH bolus of 70 U/kg will be administered” NCT07383155 ↗ |